Chongqing Pharscin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China and internationally. It offers generic drugs, traditional Chinese medicines, and food for special medical purposes in various forms, including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, ...
Chongqing Pharscin Pharmaceutical reported revenue of 774.82 million CNY for fiscal year 2024, up 12.0% from fiscal year 2023, and net income of 76.73 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 202.97 million CNY, up 7.1% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 83% of segment revenue in fiscal year 2025; Southwest Region was the largest region with 45%.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.